It is now widely acknowledged that inhibition or stimulation of osteopontin function/expression and its upstream or downstream signaling pathways by different strategies such as neutralizing antibodies, small-molecular inhibitors, aptamers, and osteopontin peptide analogs might represent a promising strategy to modulate adverse cardiac remodeling in HF of various etiologies. The gene discussed is SPP1; the disease is hydrops fetalis.